{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:35:09Z","timestamp":1769524509287,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Korean Fund for Regenerative Medicine","award":["21A0402L1-12"],"award-info":[{"award-number":["21A0402L1-12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94795-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:45:28Z","timestamp":1743792328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic effects of lomerizine on vasculopathy in Fabry disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Jong Bin","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Sang","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Won","family":"Seol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Young","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taek-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youkyeong Gloria","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heounjeong","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungjoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Suk","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Myoung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabbine","family":"Wee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Mahn","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"94795_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas, J. et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genet. 9, e1003632. https:\/\/doi.org\/10.1371\/journal.pgen.1003632 (2013).","journal-title":"PLoS Genet."},{"key":"94795_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","volume":"60","author":"SM Rombach","year":"2012","unstructured":"Rombach, S. M. et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 60, 998\u20131005. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.195685 (2012).","journal-title":"Hypertension"},{"key":"94795_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu, C. H. et al. Fabry disease and the skin: Data from FOS, the Fabry outcome survey. Br. J. Dermatol. 157, 331\u2013337. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08002.x (2007).","journal-title":"Br. J. Dermatol."},{"key":"94795_CR4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann, R. et al. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transpl. 24, 2102\u20132111. https:\/\/doi.org\/10.1093\/ndt\/gfp031 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"94795_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta, A. et al. Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Investig. 34, 236\u2013242 (2004).","journal-title":"Eur. J. Clin. Investig."},{"key":"94795_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach, S. M. et al. Vasculopathy in patients with Fabry disease: Current controversies and research directions. Mol. Genet. Metab. 99, 99\u2013108. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.004 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"94795_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345, 9\u201316. https:\/\/doi.org\/10.1056\/NEJM200107053450102 (2001).","journal-title":"N. Engl. J. Med."},{"key":"94795_CR8","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease a randomized controlled trial. J. Am. Med. Assoc. 285, 2743\u20132749. https:\/\/doi.org\/10.1001\/jama.285.21.2743 (2001).","journal-title":"J. Am. Med. Assoc."},{"key":"94795_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox, W. R. et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75, 65\u201374 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"94795_CR10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann, F. et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 119, 524\u2013529 (2009).","journal-title":"Circulation"},{"key":"94795_CR11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/asn.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain, D. P. et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18, 1547\u20131557. https:\/\/doi.org\/10.1681\/asn.2006080816 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"94795_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders, M. & Brand, E. Fabry disease: The current treatment landscape. Drugs 81, 635\u2013645. https:\/\/doi.org\/10.1007\/s40265-021-01486-1 (2021).","journal-title":"Drugs"},{"key":"94795_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057631","volume":"8","author":"B Young-Gqamana","year":"2013","unstructured":"Young-Gqamana, B. et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS ONE 8, e57631. https:\/\/doi.org\/10.1371\/journal.pone.0057631 (2013).","journal-title":"PLoS ONE"},{"key":"94795_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1750-1172-7-91","volume":"7","author":"DP Germain","year":"2012","unstructured":"Germain, D. P. et al. Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: Report from two phase 2 clinical studies. Orphanet. J. Rare Dis. 7, 91. https:\/\/doi.org\/10.1186\/1750-1172-7-91 (2012).","journal-title":"Orphanet. J. Rare Dis."},{"key":"94795_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/FJC.0b013e318247f642","volume":"60","author":"AD Ebert","year":"2012","unstructured":"Ebert, A. D., Liang, P. & Wu, J. C. Induced pluripotent stem cells as a disease modeling and drug screening platform. J. Cardiovasc. Pharmacol. 60, 408\u2013416. https:\/\/doi.org\/10.1097\/FJC.0b013e318247f642 (2012).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"94795_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102633","volume":"52","author":"HS Do","year":"2020","unstructured":"Do, H. S. et al. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. EBioMedicine 52, 102633. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102633 (2020).","journal-title":"EBioMedicine"},{"key":"94795_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ymthe.2023.02.003","volume":"31","author":"JB Choi","year":"2023","unstructured":"Choi, J. B. et al. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease. Mol. Ther. 31, 1002\u20131016. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.003 (2023).","journal-title":"Mol. Ther."},{"key":"94795_CR18","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1167\/iovs.02-1173","volume":"44","author":"Y Tamaki","year":"2003","unstructured":"Tamaki, Y. et al. Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Investig. Ophthalmol. Vis. Sci. 44, 4864\u20134871. https:\/\/doi.org\/10.1167\/iovs.02-1173 (2003).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"94795_CR19","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1167\/iovs.09-3717","volume":"50","author":"M Fitzgerald","year":"2009","unstructured":"Fitzgerald, M. et al. Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Investig. Ophthalmol. Vis. Sci. 50, 5456\u20135462. https:\/\/doi.org\/10.1167\/iovs.09-3717 (2009).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"94795_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.redox.2015.08.010","volume":"6","author":"A G\u00f6rlach","year":"2015","unstructured":"G\u00f6rlach, A., Bertram, K., Hudecova, S. & Krizanova, O. Calcium and ROS: A mutual interplay. Redox Biol. 6, 260\u2013271. https:\/\/doi.org\/10.1016\/j.redox.2015.08.010 (2015).","journal-title":"Redox Biol."},{"key":"94795_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"J-S Shen","year":"2008","unstructured":"Shen, J.-S. et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 95, 163\u2013168. https:\/\/doi.org\/10.1016\/j.ymgme.2008.06.016 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"94795_CR22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1152\/physrev.00021.2018","volume":"99","author":"S Piera-Velazquez","year":"2019","unstructured":"Piera-Velazquez, S. & Jimenez, S. A. Endothelial to mesenchymal transition: Role in physiology and in the pathogenesis of human diseases. Physiol. Rev. 99, 1281\u20131324. https:\/\/doi.org\/10.1152\/physrev.00021.2018 (2019).","journal-title":"Physiol. Rev."},{"key":"94795_CR23","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.3389\/fimmu.2018.01985","volume":"9","author":"DTB Thuan","year":"2018","unstructured":"Thuan, D. T. B. et al. A potential link between oxidative stress and endothelial-to-mesenchymal transition in systemic sclerosis. Front. Immunol. 9, 1985. https:\/\/doi.org\/10.3389\/fimmu.2018.01985 (2018).","journal-title":"Front. Immunol."},{"key":"94795_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann, F. et al. Fibrosis: A key feature of Fabry disease with potential therapeutic implications. Orphanet J. Rare Dis. 8, 116. https:\/\/doi.org\/10.1186\/1750-1172-8-116 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"94795_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","volume":"594","author":"L Choi","year":"2015","unstructured":"Choi, L. et al. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci. Lett. 594, 163\u2013168. https:\/\/doi.org\/10.1016\/j.neulet.2015.01.084 (2015).","journal-title":"Neurosci. Lett."},{"key":"94795_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00260","author":"J Ma","year":"2020","unstructured":"Ma, J., Sanchez-Duffhues, G., Goumans, M.-J. & ten Dijke, P. TGF-\u03b2-induced endothelial to mesenchymal transition in disease and tissue engineering. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/fcell.2020.00260 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"94795_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae095","author":"T Klein","year":"2024","unstructured":"Klein, T. et al. Small fibre neuropathy in Fabry disease: A human-derived neuronal in vitro disease model and pilot data. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcae095 (2024).","journal-title":"Brain Commun."},{"key":"94795_CR28","doi-asserted-by":"publisher","first-page":"eadp6182","DOI":"10.1126\/sciadv.adp6182","volume":"10","author":"M Lebas","year":"2024","unstructured":"Lebas, M. et al. Integrated single-cell RNA-seq analysis reveals mitochondrial calcium signaling as a modulator of endothelial-to-mesenchymal transition. Sci. Adv. 10, eadp6182. https:\/\/doi.org\/10.1126\/sciadv.adp6182 (2024).","journal-title":"Sci. Adv."},{"key":"94795_CR29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.freeradbiomed.2011.06.033","volume":"51","author":"S Dikalov","year":"2011","unstructured":"Dikalov, S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 51, 1289\u20131301. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.06.033 (2011).","journal-title":"Free Radic. Biol. Med."},{"key":"94795_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121891","author":"LL Walkon","year":"2022","unstructured":"Walkon, L. L., Strubbe-Rivera, J. O. & Bazil, J. N. Calcium overload and mitochondrial metabolism. Biomolecules https:\/\/doi.org\/10.3390\/biom12121891 (2022).","journal-title":"Biomolecules"},{"key":"94795_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/CIRCRESAHA.113.301651","volume":"113","author":"M Luo","year":"2013","unstructured":"Luo, M. & Anderson, M. E. Mechanisms of altered Ca2+ handling in heart failure. Circ. Res. 113, 690\u2013708. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.301651 (2013).","journal-title":"Circ. Res."},{"key":"94795_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1006\/exer.1999.0809","volume":"70","author":"N Toriu","year":"2000","unstructured":"Toriu, N. et al. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia\/reperfusion damage in rat retina. Exp. Eye Res. 70, 475\u2013484. https:\/\/doi.org\/10.1006\/exer.1999.0809 (2000).","journal-title":"Exp. Eye Res."},{"key":"94795_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00441-008-0663-z","volume":"335","author":"Y Ishii","year":"2009","unstructured":"Ishii, Y., Langberg, J., Rosborough, K. & Mikawa, T. Endothelial cell lineages of the heart. Cell Tissue Res. 335, 67\u201373. https:\/\/doi.org\/10.1007\/s00441-008-0663-z (2009).","journal-title":"Cell Tissue Res."},{"key":"94795_CR34","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot, K. D., Holmes, A. & Miners, A. H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 38, 750\u2013760. https:\/\/doi.org\/10.1136\/jmg.38.11.750 (2001).","journal-title":"J. Med. Genet."},{"key":"94795_CR35","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/blood-2003-08-2770","volume":"103","author":"H Bompais","year":"2004","unstructured":"Bompais, H. et al. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 103, 2577\u20132584. https:\/\/doi.org\/10.1182\/blood-2003-08-2770 (2004).","journal-title":"Blood"},{"key":"94795_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13578-022-00856-w","volume":"12","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Chen, J., Sun, H., Zhang, Y. & Zou, D. New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction. Cell Biosci. 12, 117. https:\/\/doi.org\/10.1186\/s13578-022-00856-w (2022).","journal-title":"Cell Biosci."},{"key":"94795_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/b978-0-12-394309-5.00006-7","volume":"298","author":"T Kalogeris","year":"2012","unstructured":"Kalogeris, T., Baines, C. P., Krenz, M. & Korthuis, R. J. Cell biology of ischemia\/reperfusion injury. Int. Rev. Cell Mol. Biol. 298, 229\u2013317. https:\/\/doi.org\/10.1016\/b978-0-12-394309-5.00006-7 (2012).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"94795_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz, A. et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol. Genet. Metab. 123, 416\u2013427. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"94795_CR39","doi-asserted-by":"publisher","first-page":"103001","DOI":"10.1016\/j.scr.2022.103001","volume":"66","author":"JB Choi","year":"2023","unstructured":"Choi, J. B., Seo, D., Do, H.-S. & Han, Y.-M. Generation of a CRISPR\/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having \u03b1-galactosidase (GLA) gene mutation (c.803_806del). Stem Cell Res. 66, 103001. https:\/\/doi.org\/10.1016\/j.scr.2022.103001 (2023).","journal-title":"Stem Cell Res."},{"key":"94795_CR40","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1182\/blood-2010-04-280719","volume":"116","author":"SW Park","year":"2010","unstructured":"Park, S. W. et al. Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK\/ERK and BMP4 signaling pathways. Blood 116, 5762\u20135772. https:\/\/doi.org\/10.1182\/blood-2010-04-280719 (2010).","journal-title":"Blood"},{"key":"94795_CR41","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nprot.2014.102","volume":"9","author":"VV Orlova","year":"2014","unstructured":"Orlova, V. V. et al. Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells. Nat. Protoc. 9, 1514\u20131531. https:\/\/doi.org\/10.1038\/nprot.2014.102 (2014).","journal-title":"Nat. Protoc."},{"key":"94795_CR42","first-page":"2012","volume":"5","author":"G Carpentier","year":"2012","unstructured":"Carpentier, G. Contribution: angiogenesis analyzer. ImageJ News 5, 2012 (2012).","journal-title":"ImageJ News"},{"key":"94795_CR43","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.stemcr.2021.06.007","volume":"16","author":"JB Choi","year":"2021","unstructured":"Choi, J. B. et al. Dysregulated ECM remodeling proteins lead to aberrant osteogenesis of Costello syndrome iPSCs. Stem Cell Rep. 16, 1985\u20131998. https:\/\/doi.org\/10.1016\/j.stemcr.2021.06.007 (2021).","journal-title":"Stem Cell Rep."},{"key":"94795_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ymeth.2016.11.016","volume":"115","author":"JF Gilles","year":"2017","unstructured":"Gilles, J. F., Dos Santos, M., Boudier, T., Bolte, S. & Heck, N. DiAna, an ImageJ tool for object-based 3D co-localization and distance analysis. Methods 115, 55\u201364. https:\/\/doi.org\/10.1016\/j.ymeth.2016.11.016 (2017).","journal-title":"Methods"},{"key":"94795_CR45","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1038\/s41598-020-60594-2","volume":"10","author":"K Pappritz","year":"2020","unstructured":"Pappritz, K. et al. Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations. Sci. Rep. 10, 3629. https:\/\/doi.org\/10.1038\/s41598-020-60594-2 (2020).","journal-title":"Sci. Rep."},{"key":"94795_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1476-7120-12-40","volume":"12","author":"S Selvaraj","year":"2014","unstructured":"Selvaraj, S. et al. Diastolic wall strain: A simple marker of abnormal cardiac mechanics. Cardiovasc. Ultrasound 12, 40. https:\/\/doi.org\/10.1186\/1476-7120-12-40 (2014).","journal-title":"Cardiovasc. Ultrasound"},{"key":"94795_CR47","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1523\/jneurosci.17-11-04275.1997","volume":"17","author":"AT Tafari","year":"1997","unstructured":"Tafari, A. T., Thomas, S. A. & Palmiter, R. D. Norepinephrine facilitates the development of the murine sweat response but is not essential. J. Neurosci. 17, 4275\u20134281. https:\/\/doi.org\/10.1523\/jneurosci.17-11-04275.1997 (1997).","journal-title":"J. Neurosci."},{"issue":"112","key":"94795_CR48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1152\/japplphysiol.01508.2011","volume":"1985","author":"D Gagnon","year":"2012","unstructured":"Gagnon, D. et al. Modified iodine-paper technique for the standardized determination of sweat gland activation. J. Appl. Physiol. 1985(112), 1419\u20131425. https:\/\/doi.org\/10.1152\/japplphysiol.01508.2011 (2012).","journal-title":"J. Appl. Physiol."},{"key":"94795_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015033","volume":"5","author":"J Marshall","year":"2010","unstructured":"Marshall, J. et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE 5, e15033. https:\/\/doi.org\/10.1371\/journal.pone.0015033 (2010).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94795-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94795-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94795-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:47:41Z","timestamp":1744285661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94795-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94795"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94795-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11355"}}